Referenser
l.
Lindstedt G, Ekman R, Femlund P, Forberg R,
Lindblad B, HellsingK, Nyström E. Kan man
lita på laboratoriet?Ökat behov av patientrela–
terad kvalitetssäkring. Läkartidningen
1999;96:4028-31.
2. Brucker-Davis F, Oldfield EH, SkarulisMC,
Doppman IL,Weintraub BD.Thyrotropin-secret–
ing pituitary tumors: diagnostic criteria, thyroid
hormone sensitivity, and treatment outcome in
25 patients followed at the national institutes of
health. J Clin Endocrino1Metab 1999;84:476-86.
3. Sapin R, d'HerbomezM, Schlienger IL,
Wemeau IL.Anti-thyrotropin antibody inter–
ference in thyrotropin assays. Clin Chem
1998;44:2557-9.
4. Whybrow PC. Behavioral and psychiatric aspects
of thyrotoxicosis. I Braverman LW,Utiger RD.
Werner and Ingbar's The thyroid. 7th ed.
Philadelphia: Lippincott-Raven 1995:607-15.
5. Klein I, Levey GS. The cardiovascular system in
thyrotoxicosis. I Braverman LW, Utiger RD.
Werner and Ingbar 's The thyroid. 7th ed.
Philadelphia:Lippincott-Raven 1995:607-15.
6. Lindstedt G, Ekman R, Femlund P, Forberg R,
Lindblad B, HellsingK, Nyström E. Medicinsk
kvalitetssäkring i klinisk kemi: thyreoideadiag–
nostiska aspekter. Uppsala: EQUALIS 1997:1-14.
7. Lindstedt G, Ekman R, Femlund P, ForbergR,
Lindblad B,HellsingK, Nyström E.Användar–
möte i endokrinologi iGöteborg l
O-
11 septem–
ber 1998. Patientprovskontroller september 1997
-september 1998. Uppsala:EQUALIS 1998:1-9.
8. Lindstedt G, Berg G, Nyström E. Förhöjt TSH–
värde skall alltid utredas.
Läkartidningen 1999;96:1734-5.
9. Weber TH,Käpyaho Kl,Tarmer P. Endogenous
interference in immunoassays in clinical
chemistry. Scand J Clin Lab Invest 1990;
50(suppl 201):77-82.
l
O.
Hedenborg G, PetterssonT, Carlström
A.
Heterophilic antibodies eausing falsely raised
thyroid-stimulating hormone result. Lancet;
1979;i i:755.
11. Boscato LM, Egan G, StuartMC. Covert cross–
reactants in a two-site immunoassay studied with
monoclonal antibodies. Anal Biochem
1985;146:393-401.
12. NahmMH, Hoffman
JW.
Heteroantibody:
phantom of the immunoassay. C!in Chem
1990;36:829.
13. Stiemer U, Lindstedt G. Kemoterapiresistent
förhöjning av -fetoproteinkoncentrationen i
serum efter operation för testikelcancer.
Klinisk Kemi iNorden 1995;2:53-7.
12
14. Cole LA, Rinne KM, Shahabi S, Omrani A.
False-positive hCG assay results leading to
unnecessary surgery and chemotherapy and
needless occurrences of diabetes and coma.
Clin Chem 1999;45:313-4.
15. Lindstedt G, Lundberg PA. Are current methods
ofmeasurement of erythropoietin (EPO) in
human plasma or serum adequate for the diagno–
sis of polycythemia vera and the assessment of
EPO deficiency? [Editorial Review]. Scand J
Clin Lab lnvest 1998;58:441-58.
16. Kaplan
TV,
Levinson SS. When is a heterophile
antibody not a heteropillie antibody?When it is
an antibody against a specific immunogen.
Clin Chem 1999;45:616-8.
17. Kricka LJ.Human anti-animal antibody inter–
ferences in immunological assays. Clin Chem
1999;45:942-56.
18. Frost SJ. Moreon heterophile and human
antianimal antibodies. Clin Chem 1999;45:2042.
19. Levinson SS, Kaplan IV. Moreon heterophile
and human antianimal antibodies: response.
Clin Chem 1999;45:2042-3.
20. Ekman R, Femlund P, Forberg R, IsakssonA,
Lindstedt G, HellsingK, Hård L, Nyström E.
Kan laboratorierna lita på diagnostikaföretagen?
Läkartidningen.Accepterat 2000.
21. Center for Devices and Radiological Health
(CDRH) Home Page. FDAHome Page. Abbott
Consent Decree Information.
22. U.S. Food and DrugAdministration. Waming
letters. FDA's Electronic Freedom ofinforma–
tion Reading Room.
Klinisk Kjemi
i
Norden l, 2000
